Hochschulschrift
Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Maße
-
30 cm
- Umfang
-
143 Bl.
- Sprache
-
Englisch
- Anmerkungen
-
Ill., graph. Darst.
Freiburg (Breisgau), Univ., Diss., 2012
- Klassifikation
-
Medizin, Gesundheit
Biowissenschaften, Biologie
- Urheber
-
Wöhrle, Franziska Ursula
- Inhaltsverzeichnis
- Rechteinformation
-
Bei diesem Objekt liegt nur das Inhaltsverzeichnis digital vor. Der Zugriff darauf ist unbeschränkt möglich.
- Letzte Aktualisierung
-
11.06.2025, 14:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Objekttyp
- Hochschulschrift
Beteiligte
- Wöhrle, Franziska Ursula
Ähnliche Objekte (12)
Phosphorylation of BECLIN-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia
LASP1 is a novel BCR-ABL substrate and a phosphorylation-dependent binding partner of CRKL in chronic myeloid leukemia
Initial decline of BCR-ABL transcript levels as early prognostic marker for patients with chronic myeloid leukemia (CML) treated with imatinib
Treatment-free remission in chronic myeloid leukemia
Somatic variant profiling in chronic phase pediatric chronic myeloid leukemia
The role of ABL/BCR in the leukemogenic potential of BCR/ABL in Philadelphia chromosome positive leukemia
The role of ABL/BCR in the leukemogenic potential of BCR/ABL in Philadelphia chromosome positive leukemia
Novel imantib resistance mechanisms in chronic myeloid leukemia
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
Myeloid cells and therapy resistance in Chronic Lymphocytic Leukemia
Phosphorylation of BECLIN-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia
LASP1 is a novel BCR-ABL substrate and a phosphorylation-dependent binding partner of CRKL in chronic myeloid leukemia
Initial decline of BCR-ABL transcript levels as early prognostic marker for patients with chronic myeloid leukemia (CML) treated with imatinib
Treatment-free remission in chronic myeloid leukemia
Somatic variant profiling in chronic phase pediatric chronic myeloid leukemia
The role of ABL/BCR in the leukemogenic potential of BCR/ABL in Philadelphia chromosome positive leukemia
The role of ABL/BCR in the leukemogenic potential of BCR/ABL in Philadelphia chromosome positive leukemia
Novel imantib resistance mechanisms in chronic myeloid leukemia
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
Myeloid cells and therapy resistance in Chronic Lymphocytic Leukemia
Phosphorylation of BECLIN-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia
LASP1 is a novel BCR-ABL substrate and a phosphorylation-dependent binding partner of CRKL in chronic myeloid leukemia
Initial decline of BCR-ABL transcript levels as early prognostic marker for patients with chronic myeloid leukemia (CML) treated with imatinib
Treatment-free remission in chronic myeloid leukemia
Somatic variant profiling in chronic phase pediatric chronic myeloid leukemia
The role of ABL/BCR in the leukemogenic potential of BCR/ABL in Philadelphia chromosome positive leukemia
The role of ABL/BCR in the leukemogenic potential of BCR/ABL in Philadelphia chromosome positive leukemia
Novel imantib resistance mechanisms in chronic myeloid leukemia
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV